AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11779889 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 to 325 mg per day)
Number of subjects: 87
Study 11779889 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg per day)
Number of subjects: 87
Study 11779889 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (975 to 1300 mg per day)
Number of subjects: 87
Study 11779889 — intervention group
Group type: COMPARATOR
Intervention: No aspirin (no antithrombotic drugs or ticlopidine)
Number of subjects: 87
Study 9842977 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg x 2
Number of subjects: 6
Study 9842977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 500 mg x 2
Number of subjects: 6
Study 9842977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg
Number of subjects: 6
Study 9842977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg with Niflumic acid (250 mg)
Number of subjects: 6
Study 9842977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg with Paracetamol (500 mg)
Number of subjects: 6
Study 9842977 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 6
Study 7734464 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix outpatient stimulant treatment
Number of subjects: 146
Study 2477936 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (750 mg/d)
Number of subjects: 84
Study 2477936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 5431082 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide, oxygen, and halothane
Number of subjects: 65
Study 5431082 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone
Number of subjects: 65
Study 5431082 — intervention group
Group type: EXPERIMENTAL
Intervention: Propanidid
Number of subjects: 65
Study 5431082 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 65
Study 31764289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL)
Number of subjects: 114
Study 31764289 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 114
Study 31560137 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (0.5‐1.0 mg/kg) administered PO once daily for up to 2 years
Number of subjects: 151
Study 31560137 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered PO once daily for up to 2 years
Number of subjects: 151
Study 31560137 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 151
Study 31560137 — intervention group
Group type: COMPARATOR
Intervention: Benazepril and Placebo
Number of subjects: 151
Study 28599199 — intervention group
Group type: EXPERIMENTAL
Intervention: 1L normal saline (NS) administered as a rapid infusion over 30 min
Number of subjects: 6
Study 28599199 — intervention group
Group type: EXPERIMENTAL
Intervention: 1L normal saline (NS) administered as a slow infusion over 120 min
Number of subjects: 6
Study 28599199 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline measurements)
Number of subjects: 6
Study 25557740 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cumulative bortezomib dose (≥39 mg/m²)
Number of subjects: 340
Study 25557740 — intervention group
Group type: COMPARATOR
Intervention: Lower cumulative bortezomib dose (<39 mg/m²)
Number of subjects: 340
Study 25557740 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cumulative bortezomib dose (≥39 mg/m²) after landmark analysis
Number of subjects: 340
Study 25557740 — intervention group
Group type: COMPARATOR
Intervention: Lower cumulative bortezomib dose (<39 mg/m²) after landmark analysis
Number of subjects: 340
Study 23256711 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery
Number of subjects: 9
Study 23256711 — intervention group
Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 9
Study 23256711 — intervention group
Group type: COMPARATOR
Intervention: Deep massage
Number of subjects: 9
Study 23256711 — intervention group
Group type: COMPARATOR
Intervention: Superficial massage
Number of subjects: 9
Study 23256711 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 9
Study 21991950 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir suppression (300 mg/m² per dose orally, three times daily for 6 months)
Number of subjects: 74
Study 21991950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 21991950 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir suppression
Number of subjects: 74
Study 19863282 — intervention group
Group type: EXPERIMENTAL
Intervention: MDIS (metered dose inhaler with spacer device)
Number of subjects: 86
Study 19863282 — intervention group
Group type: COMPARATOR
Intervention: Standard nebulizer therapy
Number of subjects: 86
Study 16923091 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin treatment (short-acting insulin 1 IU/kg/h with 30% glucose 1.5 ml/kg/h)
Number of subjects: 40
Study 16923091 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (saline)
Number of subjects: 40
Study 16923091 — intervention group
Group type: COMPARATOR
Intervention: High-dose insulin treatment and Control treatment
Number of subjects: 40
Study 14579657 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% oxymetazoline nasal spray (2 sprays, 0.1 ml/spray) 3 times daily for 4 weeks
Number of subjects: 30
Study 14579657 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 30
Study 14579657 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% oxymetazoline nasal spray
Number of subjects: 30
Study 10893356 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiographs showing cardiac enlargement
Number of subjects: 2454
Study 10893356 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiographs showing pulmonary artery enlargement
Number of subjects: 2454
Study 10893356 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiographs showing normal results
Number of subjects: 2454
Study 10893356 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiographs showing abnormal results
Number of subjects: 2454
Study 8813270 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-exchange (PE)
Number of subjects: 18
Study 8813270 — intervention group
Group type: COMPARATOR
Intervention: Sham plasma-exchange (SPE)
Number of subjects: 18
Study 1580724 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 4891
Study 1580724 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Number of subjects: 4891
Study 1580724 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Number of subjects: 4891
Study 1580724 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 4891
Study 1580724 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital mortality
Number of subjects: 4891
Study 1580724 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality in women undergoing bypass surgery
Number of subjects: 4891
Study 4016041 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for assessing microhaemorrhage
Number of subjects: 16
Study 4016041 — intervention group
Group type: EXPERIMENTAL
Intervention: Two different general anaesthetic induction regimens
Number of subjects: 16
Study 30831467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 30831467 — intervention group
Group type: EXPERIMENTAL
Intervention: MO 12c
Number of subjects: 52
Study 30831467 — intervention group
Group type: EXPERIMENTAL
Intervention: PD 12c
Number of subjects: 52
Study 30831467 — intervention group
Group type: EXPERIMENTAL
Intervention: MO 12c + PD 12c
Number of subjects: 52
Study 27830923 — intervention group
Group type: EXPERIMENTAL
Intervention: CTAR exercise
Number of subjects: 90
Study 27830923 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaker exercise
Number of subjects: 90
Study 27830923 — intervention group
Group type: COMPARATOR
Intervention: Routine treatments (Control group)
Number of subjects: 90
Study 26060880 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) titrated between 32°C and 35°C
Number of subjects: 17
Study 26060880 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 17
Study 25148375 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric nanoparticles containing curcumin
Number of subjects: 0
Study 21604891 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training intervention focusing on self-regulatory factors such as self-efficacy and active engagement.
Number of subjects: 0
Study 21604891 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training intervention with strategy usage and strategy change as predictors.
Number of subjects: 0
Study 21604891 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy change as the main predictor of memory change for text recall.
Number of subjects: 0
Study 21604891 — intervention group
Group type: EXPERIMENTAL
Intervention: Active engagement in training as a factor influencing memory gains.
Number of subjects: 0
Study 19525207 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece-based methods (desktop and portable computerized devices)
Number of subjects: 30
Study 19525207 — intervention group
Group type: COMPARATOR
Intervention: Direct observation (video recording only)
Number of subjects: 30
Study 18163056 — intervention group
Group type: EXPERIMENTAL
Intervention: Klonidine
Number of subjects: 0
Study 18163056 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric oxygenation therapy
Number of subjects: 0
Study 15057855 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields
Number of subjects: 64
Study 15057855 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 11429343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine in 7.5% glucose
Number of subjects: 100
Study 11429343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine in 0.75% glucose
Number of subjects: 100
Study 9808685 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg once daily for 10 days) with 10 mg/kg tirilazad mesylate orally
Number of subjects: 8
Study 9808685 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg once daily for 10 days) with 2 mg/kg tirilazad mesylate i.v.
Number of subjects: 8
Study 7851350 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (continuous intravenous infusion starting dose 3 mg kg‐1 h‐1)
Number of subjects: 43
Study 7851350 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (starting concentration of 1%)
Number of subjects: 43
Study 2923087 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg white in liquid-formula meals
Number of subjects: 0
Study 2923087 — intervention group
Group type: COMPARATOR
Intervention: Casein in liquid-formula meals
Number of subjects: 0
Study 2923087 — intervention group
Group type: COMPARATOR
Intervention: Whey protein in liquid-formula meals
Number of subjects: 0
Study 2923087 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme- or acid-hydrolyzed milk-protein products
Number of subjects: 0
Study 1096908 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine at 10 mg/min
Number of subjects: 0
Study 1096908 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine at 20 mg/min
Number of subjects: 0
Study 1096908 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine at 20 mg/min
Number of subjects: 0
Study 1096908 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 0
Study 29781935 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training (8 sessions over 4 weeks, 2 times per week)
Number of subjects: 14
Study 29781935 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (no training)
Number of subjects: 14
Study 31484377 — intervention group
Group type: EXPERIMENTAL
Intervention: Millet-based mid-day meals
Number of subjects: 1500
Study 31484377 — intervention group
Group type: COMPARATOR
Intervention: Control group (fortified rice-based mid-day meal)
Number of subjects: 1500
Study 31484377 — intervention group
Group type: EXPERIMENTAL
Intervention: Millet-based menu items
Number of subjects: 1500
Study 28535819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin (overt)
Number of subjects: 50
Study 28535819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (overt)
Number of subjects: 50
Study 28535819 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (overt)
Number of subjects: 50
Study 28535819 — intervention group
Group type: COMPARATOR
Intervention: Placebo (covert)
Number of subjects: 50
Study 24441732 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation systems (CANS)
Number of subjects: 214
Study 24441732 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 214
Study 23211814 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular pigment density
Number of subjects: 150
Study 21730857 — intervention group
Group type: EXPERIMENTAL
Intervention: New hearing aid
Number of subjects: 20
Study 21730857 — intervention group
Group type: COMPARATOR
Intervention: Conventional hearing aid
Number of subjects: 20
Study 19483294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 71
Study 19483294 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy
Number of subjects: 71
Study 16719026 — intervention group
Group type: EXPERIMENTAL
Intervention: Static positional stretches of the stroke‐affected shoulder twice daily and positioned the stroke‐affected upper limb in an armrest support at all other times when seated.
Number of subjects: 32
Study 16719026 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group).
Number of subjects: 32
Study 16719026 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group.
Number of subjects: 32
Study 15232326 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ) 5 to 20 mg/d
Number of subjects: 249
Study 15232326 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination (OFC) 5 to 20 mg/d olanzapine + 20 to 80 mg/d fluoxetine
Number of subjects: 249
Study 15232326 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 249
Study 11547961 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-containing drug delivery system (DDS)
Number of subjects: 63
Study 11547961 — intervention group
Group type: COMPARATOR
Intervention: 0.1% dexamethasone eyedrops (control)
Number of subjects: 63
Study 11547961 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical chloramphenicol eyedrops
Number of subjects: 63
Study 9258878 — intervention group
Group type: EXPERIMENTAL
Intervention: nRBC count in PROM
Number of subjects: 465
Study 9258878 — intervention group
Group type: EXPERIMENTAL
Intervention: nRBC count in PTL
Number of subjects: 465
Study 9258878 — intervention group
Group type: EXPERIMENTAL
Intervention: nRBC count in preeclampsia
Number of subjects: 465
Study 9258878 — intervention group
Group type: EXPERIMENTAL
Intervention: nRBC count in well‐grown, nonacidotic, nondepressed preterm infants
Number of subjects: 465
Study 8335134 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of zinc supplementation during pregnancy
Number of subjects: 494
Study 8335134 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc taste test
Number of subjects: 494
Study 8335134 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 494
Study 6643334 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 135
Study 6643334 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 135
Study 30209161 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 inactivation
Number of subjects: 168
Study 30209161 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor burden estimates (CTC counts, ctDNA fraction, and visceral metastases)
Number of subjects: 168
Study 30209161 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic groups based on TP53 status
Number of subjects: 168
Study 30209161 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation in independent mCRPC cohort (n = 202)
Number of subjects: 168
Study 28406132 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 112
Study 28406132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 25656058 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide once daily
Number of subjects: 9340
Study 25656058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study 24797300 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) with chemotherapy (idarubicin, cytarabine, and all-trans retinoic acid)
Number of subjects: 186
Study 24797300 — intervention group
Group type: COMPARATOR
Intervention: STANDARD (idarubicin, cytarabine, and all-trans retinoic acid without VPA)
Number of subjects: 186
Study 23034121 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous balloon angioplasty (PTA)
Number of subjects: 679
Study 23034121 — intervention group
Group type: COMPARATOR
Intervention: Sham PTA
Number of subjects: 679
Study 23034121 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA
Number of subjects: 679
Study 19100331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 20
Study 19100331 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 20
Study 19100331 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from cigarette smoking for 12 h (SM)
Number of subjects: 20
Study 17587852 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoe fitting guidance and wearing shoes with custom-made insoles (CMI) for 1 month
Number of subjects: 79
Study 17587852 — intervention group
Group type: COMPARATOR
Intervention: Control group had a 30-min lecture on better ways of choosing shoes
Number of subjects: 79
Study 16845131 — intervention group
Group type: EXPERIMENTAL
Intervention: L-IVRA group (lidocaine 0.5% with lornoxicam)
Number of subjects: 45
Study 16845131 — intervention group
Group type: COMPARATOR
Intervention: Control group (i.v. saline and IVRA with lidocaine 0.5%)
Number of subjects: 45
Study 16845131 — intervention group
Group type: EXPERIMENTAL
Intervention: L-IV group (intravenous lornoxicam and IVRA lidocaine 0.5%)
Number of subjects: 45
Study 12720593 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements
Number of subjects: 57
Study 12720593 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 57
Study 12720593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 12720593 — intervention group
Group type: COMPARATOR
Intervention: Memory training
Number of subjects: 57
Study 10582397 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate (CIAN)
Number of subjects: 74
Study 9156928 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen extracts (Allergovit, Allergopharma, Germany) for 7 weeks
Number of subjects: 20
Study 9156928 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 1928686 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.6 mg/kg to 2.6 mg/kg in 0.2 mg/kg increments)
Number of subjects: 216
Study 1928686 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol mixed with lignocaine (0.5 mg/ml)
Number of subjects: 216
Study 6409239 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 96
Study 6409239 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 96
Study 31560736 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% capsaicin
Number of subjects: 20
Study 31560736 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% EMLA
Number of subjects: 20
Study 31560736 — intervention group
Group type: COMPARATOR
Intervention: Vaseline (placebo)
Number of subjects: 20
Study 30932955 — intervention group
Group type: EXPERIMENTAL
Intervention: MGN1703 (TLR9 agonist); 60 mg × 2 weekly for 24 weeks
Number of subjects: 12
Study 28700718 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of diabetes-related distress (PAID scale)
Number of subjects: 181
Study 28700718 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous measures of diabetes distress
Number of subjects: 181
Study 28700718 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher age
Number of subjects: 181
Study 28700718 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 181
Study 26033508 — intervention group
Group type: EXPERIMENTAL
Intervention: BFST‐D via Skype (Internet videoconferencing)
Number of subjects: 0
Study 26033508 — intervention group
Group type: COMPARATOR
Intervention: BFST‐D via Clinic (face to face)
Number of subjects: 0
Study 23138399 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (MR; 0.5‐1 μg/kg/min)
Number of subjects: 20
Study 23138399 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (LEVO; 0.1‐0.2 μg/kg/min)
Number of subjects: 20
Study 23138399 — intervention group
Group type: COMPARATOR
Intervention: Milrinone (MR)
Number of subjects: 20
Study 23138399 — intervention group
Group type: COMPARATOR
Intervention: Levosimendan (LEVO)
Number of subjects: 20
Study 21443311 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink refusal skills training module
Number of subjects: 776
Study 21443311 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 776
Study 19637474 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of four first premolars
Number of subjects: 30
Study 19637474 — intervention group
Group type: COMPARATOR
Intervention: Extraction of two maxillary first premolars and two mandibular first molars
Number of subjects: 30
Study 19637474 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of two maxillary first premolars and two mandibular first molars with additional micro-implants for orthodontic anchorage
Number of subjects: 30
Study 16843643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine and emollient treatment (Group 1) for 1 week
Number of subjects: 20
Study 16843643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine and steroid treatment (Group 2) for 1 week
Number of subjects: 20
Study 14668584 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio-frequency energy delivery via Secca® system
Number of subjects: 50
Study 10692000 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive video‐assisted thoracic surgery (VATS)
Number of subjects: 41